Gastric cancer (GC) is not only one of the common gastrointestinal malignancies in clinic, but also the most common cancer in the world. In recent years, its morbidity has increased. The global morbidity and mortality of gastric cancer rank fifth among all malignancies. The morbidity and mortality of gastric cancer in our country ranks second among malignant tumors, which is twice as high as the world average. In rural, the number is 1.6 times of in urban. The early diagnosis of most gastric cancers is rare in majority of patients, and most of them are in intermediate or advanced stage when they are in treatment. The proportion of radical surgery is not high, and it is easy to relapse and metastasize. The 5-year survival rate is about 40%, and the treatment effect is poor, which is severely harmful to people’s health. Although the pathogenesis of gastric cancer is related to many factors, the nosogenesis is vague. The occurrence of tumors is closely related to the formation of new blood vessels. New blood vessels are the internal conditions for tumor cell proliferation and metastasis. The factors that promoting angiogenesis include more than 10 kinds of fibroblast growth factors (FGFs) and vascular endothelial growth factors (VEGF), among which VEGF is the most important regulator that promotes angiogenesis. By promoting the mitosis of vascular endothelial cells, it forms an essential matrix for the growth of vascular endothelial cells, plays a crucial regulatory role in the process of tumor angiogenesis, and participates in the occurrence and development of a variety of tumor cells. This article summarizes the research progress on the vascular endothelial growth factor’s expression in gastric cancer and prognostics follows.
| Published in | American Journal of Biomedical and Life Sciences (Volume 9, Issue 5) |
| DOI | 10.11648/j.ajbls.20210905.13 |
| Page(s) | 239-247 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Gastric Cancer, Tissue, Serum, Vascular Endothelial Growth Factor, Expression, Prognosis
| [1] | Hou JZ, Li Y. Relationship Between the Expression of S100P in Gastric Cancer Tissue and Clinical Pathology [J]. American Journal of Clinical and Experimental Medicine, 2021, 9 (3): 55-64. |
| [2] | Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin. 2018, 68 (6): 394-424. |
| [3] | Zhou JS, Zheng RS, Zhuang GH, et al. Analysis on the trend of gastric cancer incidence and age change in cancer registration regions of China [J]. J Applied Oncology 2000 to 2015 [J]. 2020, 34 (1): 1-5. |
| [4] | Song ZH, Xu XN, Li KL, et al., Research progress on etiology of gastric cancer [J]. Chin Med J Metall Indus, 2020, 37 (5): 509-511. |
| [5] | Yang L, Hou JZ, Hou ZJ. Research progress of vascular endothelial growth factor and its receptor in gastric cancer [J] Chin Med Equip. 2014, 11 (4): 68-69. |
| [6] | Wang C, Li J, Ye S, et al. Oestrogen inhibits VEGF expression and angiogenesis in triple-negative breast cancer by activating GPER-1 [J]. J Cancer, 2018, 9 (20): 3802-3811. |
| [7] | Wu JB, Tang YL, Liang XH. Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy [J]. Onco Targets Ther, 2018, 11: 6901-6909. |
| [8] | Yang YQ, Song ZY. The role of vascular endothelial growth factor receptor (KDR) in infiltration and metastasis of gastric cancer [J]. 2011, 49 (27): 98-99, 101. |
| [9] | LuoYF, Huang HY. Relationship between serum soluble vascular endothelial growth factor and its receptor and tumor [J]. Chin Clin New Med, 2014, 7 (8): 779-783 |
| [10] | Xu WZ, Liu M, Wang ZR. Effect of Xiaoyutang on serum VEGF protein content in patients with advanced gastric cancer after operation [J], Trad Chin Med, 2016, 39 (2): 425-427. |
| [11] | MaL. Biological characteristics of VEGF and its receptor and its role in tumor angiogenesis [J]. J Chin Euge& Gene, 2014, 26 (5): 146-148. |
| [12] | Wang T, Liu J, Xiao XQ. Cantharidin inhibits angiogenesis by suppressing VEGF-induced JAK1/STAT3, ERK and AKT signaling pathways [J]. Arch Pharm Res. 2015, 38 (2): 282-289. |
| [13] | Byun HJ, Darvin P, Kang DY, et al. Silibinindownregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells [J]. Oncol Rep, 2017, 37 (6): 3270-3278. |
| [14] | Lieto E, Ferraraccio F, Orditura M, et al. GaliziaG. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients [J]. Ann Surg Oncol, 2008, 15 (1): 69-79. |
| [15] | Sile Chen, Xinhua Zhang, Jianjun Peng, et al. VEGF promotes gastric cancer development by upregulating CRMP4 [J]. Oncotarget. 2016, 7 (13): 17074-17086. |
| [16] | Zhao DQ, Chen J, Wu YF, et al. Correlation between Vascular Endothelial Growth Factor and Somatostatin Receptor with Progression and Prognosis in Gastric Cancer [J]. Hepatogastroenterology, 2014, 61 (132): 1154-1158. |
| [17] | Zho UQ, Zhang HY. Expressions of HER-2 protein and VEGF in gastric cancer tissues and their mutual relationships [J]. J North Sichuan Med College2016, 31 (5): 690-692. |
| [18] | Liao J, Yang XP Expression of VEGF in gastric carcinoma and its relationship with clinicopathological features and prognosis [J]. Clin Med Rese and Prac, 2018, 3 (9): 25-27. |
| [19] | Li J. Expression of VEGF and p53 in chronic atrophic gastritis and gastric cancer [J]. J Henan Med Colle, 2018, 30 (2): 113-115. |
| [20] | Xia BX, Li F, Xu J. et al. Expression of interleukin-33 and vascular endothelial growth factor C in gastric cancer and its clinical significance [J]. Chong Qing Med, 2016, 46 (15): 2056-2059 |
| [21] | Fan ZJ, Zou YJ, Zheng WL. VEGF-C protein expression and its clinical significance in patients with advanced gastric cancer [J]. OncoProg, 2017, 15 (12): 1420-1422. |
| [22] | Liao XW, Huang BF, Xiao LH, et al. The Meta-analysis of the Expression of COX-2, VEGF-C in Gastric Carcinoma and Their Correlations with Lymphnode Metastasis [J]. Chin Fore Med &Rese, 2017, 15 (26): 8-10. |
| [23] | Zhang YH, Yan, W, QiaoBJ, et al. Expression and significance of COX-2 and VEGF-C protein in gastric cancer and precancerous lesions [J]. J Clin&Expe Med 2018, 17 (10): 1040-1043. |
| [24] | LiuJ, JiZG, BiCY, et al. Expression and correlation of HMGB1 and VEGF-D in gastric carcinoma tissue [J]. J Clin&Expe Med, 2017, 16 (18): 1796-1800. |
| [25] | Tao HQ, Lin YJ, Wang RN, et al. Role of vascular endothelial growth factor expression in infiltration and metastasis of gastric cancer [J]. J Chin Dige, 1998, 18 (5): 287-292. |
| [26] | Yang Q, Ye ZY, Zhang ZX, et al. Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis [J]. Anat Rec (Hoboken), 2010, 293 (12): 2012-2019. |
| [27] | Zhao Y, Wang YZ. Expression and clinical significance of E-cadherin, MMP-2 and MMP-9 in gastric cancer [J]. Jiang Su Med, 2013, 39 (9): 1034-1036, 1117. |
| [28] | Chen J, Tang D, Wang S, et al. High expressions of galectin-1 and VEGF are associated with poor prognosis in gastric cancer patients [J]. Tumour Biol. 2014, 35 (3): 2513-2519. |
| [29] | Yan XF. Expression and clinical significance of COX-2, VEGF and MMP-9 in gastric cancer [J]. Chin Med Guide, 2016, 14 (10): 98-99. |
| [30] | Yang F, Li AM, Jing DH. Correlation between expression of VEGF and DCs infiltration density in gastric cancer tissues [J]. J Hainan Med Univ, 2016, 22 (1): 1-4. |
| [31] | Pang L, Wang J, Fan Y, et al. Correlations of TNM staging and lymph node metastasis of gastric cancer with MRI features and VEGF expression [J]. Cancer Biomark. 2018, 23 (1): 53-59. |
| [32] | Jayson GC, Zhou C, Backen A, et al. Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer [J]. Nat Commun, 2018, 9 (1): 4672. |
| [33] | Chen XJ, Xu L, Chen ZW, et al. Expression of CD147 and VEGF in Gastric Carcinoma and its Clinical Significance [J]. J Jinzhou Med Univ, 2018, 39 (5): 1-3. |
| [34] | Chen XJ, Li HC, XuL, et al. Expression and clinical significance of Girdin and VEGF in gastric cancer [J]. J Qiqihar Med Univ, 2019, 40 (1): 1-3. |
| [35] | LiL, Gu HZ. Expression of vascular endothelial growth factor-A and α-Adducin in gastric cancer and its correlation with clinicopathological features and prognosis [J]. Int J Dig Dis, 2019, 39 (3): 216-221. |
| [36] | Zhao ZY, Su JM, Cheng ZQ, et al. Expression of Sox2 and VEGF-C in gastric cancer and its clinical significance [J]. Expe Lab Med, 2019, 37 (4): 747-750. |
| [37] | Pu XY, Zhang YQ, Jia HY. Expression of COX-2, VEGF and VEGF-C protein in gastric cancer and its clinical significance [J]. Chin Fore Med & Rese, 2018, 16 (20): 53-54. |
| [38] | Hu NJ, Wang HL. Expression and clinical significance of MMP-11, MMP-12 and VEGF-D in gastric adenocarcinoma [J]. J Shanxi Med, 2019, 48 (5): 554-560. |
| [39] | Karayiannakis AJ, Bolanaki H, Syrigos KN, et al. Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis [J]. Cancer Lett, 2003, 94 (1): 119-124. |
| [40] | Zhou HY, Ye GX, Wang SW, et al. Clinical study of VEGF levels in serum and tumor tissue of patients with gastric cancer [J]. JWorld Onco, 2004, 39 (4): 349-350, 359. |
| [41] | Hu M, Fan ZL, Wang XH. Expression and significance of vascular endothelial growth factor in serum of patients with gastric cancer [J]. J Qinghai Med Colle, 2008, 29 (1): 36-38. |
| [42] | Kang SY, Li J. Study on the expression of VEGF in serum and MVD in cancer tissue of patients with gastric cancer [J]. J Inner Mongolia Med Colle, 2009, 31 (1): 13-18. |
| [43] | Mysliwiec P, Pawlak K, Bandurski R, et al. Soluble angiogenesis markers in gastric tumor patients [J]. Folia Histochem Cytobiol, 2009, 47 (1): 81-86. |
| [44] | Hǎlmaciu I, Gurzu S, Dobreanu M, et al. The most studied VEGF molecule is VEGF-A (Vascular Endothelial Growth Factor). Its involvement in various neoplastic processes represents an intensely controversial hypothesis [J]. Rev Med ChirSoc Med Nat Iasi, 2012, 116 (2): 446-451. |
| [45] | Lei Liu, Ma XL, Xiao ZL, et al. Prognostic value of vascular endothelial growth factor expression in resected gastric cancer [J]. Asian Pac J Cancer Prev. 2012; 13 (7): 3089-3097. |
| [46] | Villarejo-Campos P, Padilla-Valverde D, MartinRM, et al. Serum VEGF and VEGF-C values before surgery and after postoperative treatment in gastric cancer [J]. ClinTransl Oncol, 2013, 15 (4): 265-270. |
| [47] | Bilgiç CI, Tez M. Serum VEGF levels in gastric cancer patients: correlation with clinicopathological parameters [J] Turk J Med Sci. 2015, 45 (1): 112-117. |
| [48] | Wang SD. Changes and significance of serum VEGF, MMP-9 and endostatin in patients with gastric cancer [J]. Shandong Med, 2011, 51 (38): 67-68. |
| [49] | Yao J. Clinical significance of combined detection of IL-6, CA724 and VEGF in patients with gastric cancer [J]. Med Fron, 2018, 8 (31): 141-142. |
| [50] | Liu B, Zhou F, Yang F. bFGF, VEGF and CE were used to predict the efficacy of apatinib in the treatment of advanced gastric cancer [J]. World Latest Med Infor (Electronic Version) 2020, 20 (1): 166-167. |
| [51] | Dong L, Xia M, Shang KX, et al. Changes and clinical significance of serum VEGF, MMP-2 and MMP-9 levels in patients with gastric cancer before and after surgery [J]. J Mol Diag Ther, 2020, 12 (9): 1221-1225. |
APA Style
Li Hongyan, Zhang Shuli, Hou Jianzhang. (2021). The Vascular Endothelial Growth Factor’s Expression in Gastric Cancer and Progress in Prognostic Research. American Journal of Biomedical and Life Sciences, 9(5), 239-247. https://doi.org/10.11648/j.ajbls.20210905.13
ACS Style
Li Hongyan; Zhang Shuli; Hou Jianzhang. The Vascular Endothelial Growth Factor’s Expression in Gastric Cancer and Progress in Prognostic Research. Am. J. Biomed. Life Sci. 2021, 9(5), 239-247. doi: 10.11648/j.ajbls.20210905.13
AMA Style
Li Hongyan, Zhang Shuli, Hou Jianzhang. The Vascular Endothelial Growth Factor’s Expression in Gastric Cancer and Progress in Prognostic Research. Am J Biomed Life Sci. 2021;9(5):239-247. doi: 10.11648/j.ajbls.20210905.13
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajbls.20210905.13,
author = {Li Hongyan and Zhang Shuli and Hou Jianzhang},
title = {The Vascular Endothelial Growth Factor’s Expression in Gastric Cancer and Progress in Prognostic Research},
journal = {American Journal of Biomedical and Life Sciences},
volume = {9},
number = {5},
pages = {239-247},
doi = {10.11648/j.ajbls.20210905.13},
url = {https://doi.org/10.11648/j.ajbls.20210905.13},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.20210905.13},
abstract = {Gastric cancer (GC) is not only one of the common gastrointestinal malignancies in clinic, but also the most common cancer in the world. In recent years, its morbidity has increased. The global morbidity and mortality of gastric cancer rank fifth among all malignancies. The morbidity and mortality of gastric cancer in our country ranks second among malignant tumors, which is twice as high as the world average. In rural, the number is 1.6 times of in urban. The early diagnosis of most gastric cancers is rare in majority of patients, and most of them are in intermediate or advanced stage when they are in treatment. The proportion of radical surgery is not high, and it is easy to relapse and metastasize. The 5-year survival rate is about 40%, and the treatment effect is poor, which is severely harmful to people’s health. Although the pathogenesis of gastric cancer is related to many factors, the nosogenesis is vague. The occurrence of tumors is closely related to the formation of new blood vessels. New blood vessels are the internal conditions for tumor cell proliferation and metastasis. The factors that promoting angiogenesis include more than 10 kinds of fibroblast growth factors (FGFs) and vascular endothelial growth factors (VEGF), among which VEGF is the most important regulator that promotes angiogenesis. By promoting the mitosis of vascular endothelial cells, it forms an essential matrix for the growth of vascular endothelial cells, plays a crucial regulatory role in the process of tumor angiogenesis, and participates in the occurrence and development of a variety of tumor cells. This article summarizes the research progress on the vascular endothelial growth factor’s expression in gastric cancer and prognostics follows.},
year = {2021}
}
TY - JOUR T1 - The Vascular Endothelial Growth Factor’s Expression in Gastric Cancer and Progress in Prognostic Research AU - Li Hongyan AU - Zhang Shuli AU - Hou Jianzhang Y1 - 2021/09/30 PY - 2021 N1 - https://doi.org/10.11648/j.ajbls.20210905.13 DO - 10.11648/j.ajbls.20210905.13 T2 - American Journal of Biomedical and Life Sciences JF - American Journal of Biomedical and Life Sciences JO - American Journal of Biomedical and Life Sciences SP - 239 EP - 247 PB - Science Publishing Group SN - 2330-880X UR - https://doi.org/10.11648/j.ajbls.20210905.13 AB - Gastric cancer (GC) is not only one of the common gastrointestinal malignancies in clinic, but also the most common cancer in the world. In recent years, its morbidity has increased. The global morbidity and mortality of gastric cancer rank fifth among all malignancies. The morbidity and mortality of gastric cancer in our country ranks second among malignant tumors, which is twice as high as the world average. In rural, the number is 1.6 times of in urban. The early diagnosis of most gastric cancers is rare in majority of patients, and most of them are in intermediate or advanced stage when they are in treatment. The proportion of radical surgery is not high, and it is easy to relapse and metastasize. The 5-year survival rate is about 40%, and the treatment effect is poor, which is severely harmful to people’s health. Although the pathogenesis of gastric cancer is related to many factors, the nosogenesis is vague. The occurrence of tumors is closely related to the formation of new blood vessels. New blood vessels are the internal conditions for tumor cell proliferation and metastasis. The factors that promoting angiogenesis include more than 10 kinds of fibroblast growth factors (FGFs) and vascular endothelial growth factors (VEGF), among which VEGF is the most important regulator that promotes angiogenesis. By promoting the mitosis of vascular endothelial cells, it forms an essential matrix for the growth of vascular endothelial cells, plays a crucial regulatory role in the process of tumor angiogenesis, and participates in the occurrence and development of a variety of tumor cells. This article summarizes the research progress on the vascular endothelial growth factor’s expression in gastric cancer and prognostics follows. VL - 9 IS - 5 ER -
Information
Email: